<原著>ヒト脾細胞由来lymphokine activated killer(LAK)細胞の誘導およびその臨床応用への検討
スポンサーリンク
概要
- 論文の詳細を見る
It is reported that the lymphokine-activated killer (LAK) cells, induced by culturing human peripheral blood lymphocytes together with interleukin 2 (IL-2), exhibit a cytotoxic activity, in vitro, not only against free tumor cells, but also against autologous solid tumor cells. The author, using a spleen removed during operations on certain types of tumors, attempted to induce LAK cells and apply them for the treatment of tumors. The spleen is an organ, which possesses a great quantity of lymphocytes, and if a sufficient amount of LAK cells can be induced from this organ, it provides an excellent possibility for clinical application. Firstly, the author investigated the possibility of inducing LAK cells from the splenocytes of tumor-bearing patients, the cytotoxic activity of obtained LAK cells, and the method of induction of tumoricidal effector cells in a sufficient quantity for clinical application. As a result, from the splenocytes of patients of gastric cancer, LAK cells having an activity against cultured tumor cells, could be induced by culturing the splenocytes for four days, regardless of the phase of advancement of the gastric cancer. These LAK cells exhibited, in vitro, tumoricidal activity even on the same patient's own gastric cancer cells. Besides, when the splenocytes were cultured together with IL-2 for more than four days, the number of cells increased dramatically. That is, from 10^6 splenocytes, 24×10^6 tumoricidal effector cells were produced after a 14-day culturing, and the cell damaging activity was very high. From patients of liver cancer, similarly, LAK cells with a high tumoricidal activity could be induced from the splenocytes. In order to study the anti-tumor effect of LAK cells in vivo, 5×10^7 LAK cells was injected into the tumar of nude mice in which human gastric cancer cells has been transplanted. As a result, in the LAK cell injection group, the growth of tumor was markedly inhibited, as compared to the control group injected with fresh splenocytes. Seeing that a mass quantity of LAK cells as tumoricidal effector cells was obtainable from splenocytes and also that the anti-tumor effect was proven in vivo, the possibility of clinical application of splenocyte-derived tumoricidal effector cells is suggested.
- 近畿大学の論文
- 1986-09-25
著者
関連論文
- 17.ヒト脾細胞由来LAK細胞のadoptive immunotherapyへの応用に関する検討
- 胃癌患者における腹腔滲出細胞の抗腫瘍活性とOK432術前投与によるその変動効果
- W4-8 Interleukin 2 (IL-2) の脾動注による新しい消化器癌補助免疫療法の開発とその効果判定としての抹消血リンパ球機能測定の意義(第28回日本消化器外科学会総会)
- 367 clearing 法による胃癌の所属リンパ節転移と組織学的反応の検討(第27回日本消化器外科学会総会)
- 13.OK-432術前投与による腹腔内播種抑制効果とその機構に関する実験的研究
- 胃癌に合併した黒色表皮腫の3例
- 胃癌におけるα-fetoprotein高値症例の検討
- スキルス胃癌におけるestrogen receptorに関する組織化学的検討
- 21.ヒト脾細胞を用いた抗腫瘍エフェクター細胞の誘導とその臨床応用への検討
- 407 血清 AFP と血清 CEA による胃癌手術効果の評価と追跡調査(第20回日本消化器外科学会総会)
- WII-10 摘出脾より誘導された Lymphokine-activated killer cell (LAK) による消化器癌術後の受動免疫療法への試み(第24回日本消化器外科学会総会)
- ヒト脾細胞由来lymphokine activated killer(LAK)細胞の誘導およびその臨床応用への検討
- ヌードマウス継代による複数の腫瘍マーカーを産生するヒト胃癌(KUM•MK-2) の樹立 : CEA, CA19-9, KM01産生ヒト胃癌